Browse > Article

The possible predicting factor of the plantar ulcer in patients with leprosy  

Kim, Jong-Pill (Institute for Leprosy Research, Korean Hansen Welfare Association)
Kim, Yeon-Sil (Institute for Leprosy Research, Korean Hansen Welfare Association)
Publication Information
Korean leprosy bulletin / v.41, no.2, 2008 , pp. 23-35 More about this Journal
Keywords
Citations & Related Records
연도 인용수 순위
  • Reference
1 Lockwood DN, Suneetha S. Leprosy: too complex a disease for a simple elimination paradigm. Bull World Health Organ. 2005:83(3): 230-235
2 Ganapati R, Pai VV, Kingsley S. Disability prevention and management in leprosy: a field experience. Indian J Dermatol Venereol Leprol. 2003;69(6):369-374
3 Nations SP, Barohn RJ: Peripheral Neuropathy Due to Leprosy. Curr Treat Options Neurol. 2002:4(3):189-196   DOI   ScienceOn
4 Srinivasan H. Disability and rehabilitation in leprosy: issues and challenges. Int J Lepr. 2000:72:317-37
5 Walker SL, Lockwood DN. Leprosy. Clin Dermatol. 2007:25(2): 165-72   DOI   ScienceOn
6 Sehgal VN, Sharma PK. Patterns of deformities/disabilities in urban leprosy. Ind J Lepr. 1985:57:183-197
7 Prakash K, Aggarwal R. Sehgal VN. Significance of antibodies to phenolic glycolipid-I in leprosy diagnosis. J Dermatol. 1992:19:953-958   DOI
8 Roche PW, Britton WJ, Failbus SS, et al. Operational value of serological measurements in multibacillary leprosy patients: clinical and bacteriological correlates of anti body responses. Int J Lepr Other Mycobact Dis. 1990:58(3) :480-490
9 Scollard DM, Adams LB, Gillis TP, et al. The continuing challenges of leprosy. Clin Microbiol Rev. 2006:19(2):338-381   DOI   ScienceOn
10 Korean Hansen Welfare Association. Current Situation and Major Indicator of Hansen Serve Programme in Korea. Uiwang, Korean Hansen Welfare Association, 2000, pp5-26
11 Sharma P. Kar HK. Beena KR. et al. Disabilities in multibacillary leprosy patients :before. during and after multidrug therapy. Ind J Lepr. 1996:68:127-136
12 van Brakel WH. Disability and leprosy: the way forward. Ann Acad Med Singapore. 2007:36(1):86-7
13 Agrawal A, Pandit L, Dalal M, et al. Neurological manifestations of Hansen's disease and their management. Clin Neurol Neurosurg. 2005;107(6):445-54   DOI   ScienceOn
14 Bell-Krotoski JA. "Pocket" filaments and specifications for the Semmes-Weinstein Monofilaments. J Hand Ther. 1990:3(1): 26 - 31   DOI
15 Kim KH. Ha YM. Suh JJ. at al. A study of the medical factors affected social rehabilitation of leprosy patients. Korean Leprosy Bulletin. 1968:5(1)51-66
16 Klatser PR. de Wit MY, Fajardo TT, et al.: Evaluation of Mycobacterium leprae antigens in the monitoring of a dapsone-based chemotherapy of previously untreated lepromatous patients in Cebu, Philippines. Lepr Rev. 1988:60:178-186
17 Ooi WW, Srinivasan J. Leprosy and the peripheral nervous system: basic and clinical aspects. Muscle Nerve. 2004:30(4) :393-409   DOI   ScienceOn
18 Saha S. Das KK. Disability pattern amongst leprosy cases in an urban area (Calcutta). Ind J Lepr. 1993:65:305-314
19 Mitchell PD.: The threshold for protective sensation that prevents neuropathic ulceration on the plantar aspect of the foot: a study of leprosy patients in a rural community in India. Lepr Rev. 2001:72(2):143-150
20 Nienhuis WA, van Brakel WH, Butlin CR, et al. Measuring impairment caused by leprosy: inter-tester reliability of the WHO disability grading system. Lepr Rev. 2004:75(3):221-232
21 Roche PW, Britton WJ, Failbus SS, et al. Serological responses in primary neuritic leprosy. Trans R Soc Trop Med Hyg. 1991:85(2) :299-302   DOI   ScienceOn
22 Lefford MJ. Hunegnaw M. Siwik E. The value of IgM antibodies to PGL-I in the diagnosis of leprosy. Int J Lepr Other Mycobact Dis. 1991:59:432-440
23 Bryceson A, Pfaltzgraff RE. Leprosy. New York: Churchill Livingstone, 1990, pp133-151
24 Kim JP. Kim YS. Ko YH. The analysis of physical deformity of the persons inflicted with leprosy basis on outpatients visited hospital. Korean Leprosy Bulletin. 2003:36(1):35-54
25 Ng V, Zanazzi G, Timpl R. etal. Role of the cell wall phenolic glycolipid-1 in the peripheral nerve predilection of Mycobacterium leprae. 2000:27:103(3):511-524
26 van Brakel WH, Nicholls PG, Das L, Barkataki P, et al. The INFIR Cohort Study: investigating prediction, detection and pathogenesis of neuropathy and reactions in leprosy. Methods and baseline results of a cohort of multibacillary leprosy patients in north India. Lepr Rev. 2005:76:14-34
27 Kim IK, Kim JP. Disability, deformity and rehabilitation, In Society of Korean Leprologist ed. Leprosv . 1st ed. Uiwang : Korean Hansen Welfare Association, 2005, pp406-463
28 Roche PW. Britton WJ. Failbus SS et al.: Heterogeneity of serological responses in paucibacillary leprosy: differential responses to protein and carbohydrate antigens and correlation with clinical parameters. Int J Lepr. 1990:58:319-327
29 Jardim MR, Antunes SL, Simons B, et al. Role of PGL-I antibody detection in the diagnosis of pure neural leprosy. Lepr Rev. 2005:76(3) :232-240
30 Krishnamoorthy KV, Santaram V, Behera M, Pramanik JL: Incidence of plantar ulcer. The Star. 1991: 50, 8-9
31 Neill MA, Klebanoff SJ. The effect of phenolic glycolipid-1 from MYcobacterium leprae on the antimicrobial activity of human macrophages. 1988: 1: 167(1) :30-42   DOI   ScienceOn
32 Baumgart KW. Britton WJ. Mullins RJ et al. Subclinical infection with Mycobacterium leprae-a problem for leprosy control strategies. Trop Med Hyg. 1993:87:412-415   DOI   ScienceOn
33 Stearns AT. Leprosy: a problem solved by 2000? Lepr Rev. 2002;73(3) :215-224
34 Yawalkar SJ. Leprosy 7th ed. Basle : Novartis Foundation, 2002, pp91-99
35 Kim YP, Park SD. Clinical studies of plantar ulcers in leprosy patients. Korean Leprosy Bulletin. 1985:18(1):29-40
36 Anderson AM, van Brakel WH. Age specific normal thresholds for sensibility testing with monofilaments in a Nepali population. Int J Lepr. 1998:66:69A
37 Prakash K. Sehgal VN, Aggarwal R. Evaluation of phenolic glycolipid-I (PGL-I) antibody as a multi drug therapy (MDT) monitor. J Dermatol. 1993:20: 16-20   DOI
38 Singhi MK, Ghiya BC, Gupta D, et al. Disability rates in leprosy. Indian J Dermatol Venereol Leprol. 2004:70(5):314-316
39 Cho SN, Fujiwara T, Hunter SW, et al. Use of an artificial antigen containing the 3,6-di-methyl-D-glucopyr anosyl epitope for the serodiagnosis of leprosy. J Infect Dis. 1984:140:311-322
40 de Freitas MR. Infectious neuropathy. Curr Opin Neurol. 2007:20(5):548-552   DOI   ScienceOn
41 Mehra V ,Brennan PJ, Rada E, et al. Lymphocyte suppression in leprosy induced by unique M. leprae glycolipid. 1984: 308(5955): 194-196   DOI   ScienceOn
42 Thappa DM. Kaur S. Sharma VK. Disability index of hands and feet in patients attending an urban leprosy clinic. Ind J Lepr. 1990:62:328-337
43 Spinvasin H. Managemnet of Ulcers in Neurologically Impaired Feet In PAL. In: Schwarz R, Brandsma W, ed. Surgical Reconstruction & Rehabilitation in Leprosy. 1st ed, Ekta. 2004, pp193-226
44 Kim KH. Koh OJ. Report on the physical deformities in leprosy patients. Korean Leprosy Bulletin. 1963: 2(1)77-82
45 Roche PW, Britton WJ, Failbus SS et al. Serological monitoring of the response to chemotherapy in leprosy patients. Int J Lepr Other Mycobact Dis. 1993:61:35-43
46 Lavery LA, Armstrong DG, Vela SA, et al. Practical criteria for screening patients at high risk for diabetic foot ulceration. Arch Intern Med. 1998: 158: 157 - 162   DOI   ScienceOn
47 WHO Expert Committee on Leprosy. 4th report: Geneva. WHO. 1970. pp. 26-31
48 Schuring RP, Moet FJ, Pahan D, et al. Association between anti-PGL-I IgM and clinical and demographic parameters in leprosy. Lepr Rev. 2006:77(4) : 343-355
49 WHO. Global leprosy situation, beginning of 2008. Wkly Epidemiol Rec. 2008;15;83(33):293-300
50 Kalla G, Kachhawa D, Salodkar A. Disabilities in leprosy. Ind J Lepr. 2000; 68: 182-184
51 Chan J, Fujiwara T, Brennan P, et al. Microbial glycolipids : possible virulence factor s that scavenge oxygen radicals. Proc NatlAcad Sci USA. 1989:86(7):2453-2457
52 Roche PW, Britton WJ, Failbus SS et al. Operational value of serological measurements in multibacillary leprosy patients: clinical and bacteriological correlates of antibody response. Int J Lepr. 1990:58:480-490
53 Nicholls PG, Bakirtzief Z, van Brakel WH, et al. Risk factors for participation restriction in leprosy and development of a screening tool to identify individuals at risk. Lepr Rev. 2005:76:305-15
54 van Brakel WH. Peripheral neuropathy in leprosy and its consequences. Lepr Rev. 2000:71: Suppl S146 - S153
55 Cho SN. Kim SH, Cellona RV etal: Prevalence of IgM antibodies to phenolic glycolipid I among household contacts and controls in Korea and the Philippines. Lepr Rev. 1992:63: 12-20
56 Oskam L,Slim E,Buhrer-Sekula S. Serology: recent developments, strengths, limitations and prospects: a state of the art overview. 2003:74(3): 196-205
57 Selvaraj G. Prabhakar N. Muliyil J. Incidence of disabilities among multibacillary cases after initiation of MDT and factors associated with the risk of developing disabilities. Ind J Lepr. 1998:70: 11-16
58 Buhrer SS. Smits HL. Gussenhoven GC. et al. A simple dipstick assay for the detection of antibodies to phenolic glycolipid-I of Mycobacterium leprae. Am J Trop Med Hyg. 1998:58(2):133-136   DOI
59 Schlesinger LS, Horwitz MA. Phenolic glycolipid-1 of Mycobacterium leprae binds complement component C3 in serum and mediates phagocytosis by human monocytes. J Exp Med. 1991:1:174(5):1031-1038   DOI   ScienceOn